Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) EPS (Weighted Average and Diluted) (2020 - 2023)

Alx Oncology Holdings' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.92 for Q4 2023.

  • For Q4 2023, EPS (Weighted Average and Diluted) fell 22.67% year-over-year to -$0.92; the TTM value through Dec 2023 reached -$3.74, down 23.43%, while the annual FY2025 figure was -$1.9, 26.36% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2023 was -$0.92 at Alx Oncology Holdings, up from -$1.24 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.4 in Q2 2021 and bottomed at -$1.24 in Q3 2023.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.78 (2022), against an average of -$0.79.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 30.53% in 2021 before it crashed 102.5% in 2022.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.02 in 2020, then soared by 30.53% to -$0.71 in 2021, then decreased by 6.31% to -$0.75 in 2022, then decreased by 22.67% to -$0.92 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EPS (Weighted Average and Diluted) are -$0.92 (Q4 2023), -$1.24 (Q3 2023), and -$0.84 (Q2 2023).